BOLD · Boundless Bio
Conviction · Low · more likely to lag the S&P 500 over the next three months
Wrong if: a daily close above $3.00
Note written ·
Price against the kill line
16.7% clear of its kill line on the 13 November 2026 close.
How to read this
This note expects the shares to lag the market, so its kill line sits above the price: a close above the red mark would prove the view wrong. Prices run from low on the left to high on the right. The dot is where the stock closed on 13 November 2026, left of the mark while it is below the line; a dot right of the mark has closed through it.
The scale is stretched near the line, so close calls are easy to see. More than 8% from the line, the stock reads well clear, with a hollow dot to show the figure is off the drawn scale.
The kill line is the research note's own test. The portfolio sells on business facts, not on a price. How the portfolio decides
Three months against the kill line
Daily closes, to . Red: the kill line, a daily close above $3.00, on record since 11 November 2026. The shares are down 11.7% since the close; the S&P 500 is down 2.1% over the same sessions. Figures in the note can cover a different window.
Kill line
A daily close above $3.00, near the 52-week intraday high of $3.16 set on 24 August 2026, which would show the shares leading the S&P 500 and prove the lag call wrong.
Research onlyNot in the portfolio.
Catalyst
Key figures from the filings · Health Care
Quarter to 30 September 2026, filed 10 November 2026; valuation at the 13 November 2026 close
- Free cash flow, four quarters ($M)
- −57.4
- Net cash, cash less debt ($M)
- 62.9
- Free-cash-flow yield (%)
- −97.2
All filed numbers
What Boundless Bio reports to the SEC in its quarterly and annual filings. Each group states its period and filing date once; a figure dated otherwise says so. Built from the filings known on .
| Pre-tax income ($M) | Not reported |
| Net income ($M) four quarters: −55.5 | −5.4 |
| Diluted shares, change on a year (%) against the quarter to 30 September 2025 | +2.1 |
| Operating cash flow ($M) | −56.9 |
| Capital spending ($M) | 0.5 |
| Free cash flow ($M) | −57.4 |
| Cash and short-term investments ($M) | 62.9 |
| Debt ($M) | None reported |
| Net cash, cash less debt ($M) no debt reported | 62.9 |
| Deferred revenue ($M) | Not reported |
| Backlog, orders not yet delivered ($M) | Not reported |
| Receivables ($M) | Not reported |
| Inventory ($M) | Not reported |
| Shareholders' equity ($M) | 61.7 |
| Market value ($M) | 59.0 |
| Enterprise value, market value plus net debt ($M) no debt reported | −3.9 |
| Enterprise value to sales (×) | Not available |
| Enterprise value to operating income (×) | Not meaningful |
| Price to earnings (×) | Not meaningful |
| Price to book value (×) | 1.0 |
| Free-cash-flow yield (%) | −97.2 |
Short interest (FINRA, settled 15 October 2026, published 26 October 2026): 3.3% of shares outstanding sold short, 4.6 days of average trading to cover, +1.3% since the previous report.
| Window | Bought | Sold |
|---|---|---|
| 90 daysfrom | $458K | $54K |
| 12 monthsfrom | $2.0M | $94K |
The thesis
Boundless Bio is a merger-completion story, and the evidence favors lagging the S&P 500 over the next three months. The Serapha Bio deal offers a planned $44–48 million aggregate cash dividend plus about 3.8% of the combined company, and the 3 December 2026 shareholder meeting and a declared per-share dividend settle what that is worth.
The proxy statement and prospectus (Form 424B3), dated 3 November 2026, sets the special meeting for 3 December 2026 at 11:00 a.m. Pacific Time, online. The record date for voting was 20 October 2026, when 23,188,581 shares were outstanding. The per-share dividend, its record date and its ex-dividend date are still undeclared.
The shares closed at $2.46 on 12 November 2026 and have held between $2.41 and $2.46 across the sessions from 5 November 2026. The three-month price change is −13.1%, and the shares sit 22.2% below the 52-week intraday high of $3.16 set on 24 August 2026. The company filed its quarterly report (Form 10-Q) on 10 November 2026 without changing the deal terms in the prospectus.
Bullish and bearish views on Boundless Bio, Inc.
The bull case on Boundless Bio, Inc. (BOLD), in brief: the vote date is fixed. The bear case: net cash keeps falling.
Bull case
- The vote date is fixed. The 424B3 dated 3 November 2026 sets the special meeting for 3 December 2026, and the company expects closing in the fourth quarter of 2026. Shareholder approval is the main remaining closing condition inside the window.
- The cash return is sized. The 424B3 describes an aggregate pre-closing special dividend of about $44–48 million, tied to Boundless net cash above zero at closing. A declaration converts that range into a per-share amount.
- Financing is documented. The prospectus describes a Serapha pre-closing financing of about $92 million, on top of a Series A financing of about $138 million.
- A 10% owner keeps buying. Kevin Tang reported open-market purchases on Form 4 at $2.33–$2.37 on 16 October to 20 October 2026 (149,474 shares), and at $2.40 on 27 October 2026, 3 November to 5 November 2026 and 6 November to 10 November 2026 (the last filed 10 November 2026). The same holder sold 18,300 shares at $2.97 on 26 August 2026.
Bear case
- Net cash keeps falling. Cash, cash equivalents and short-term investments were $62.9 million on 30 September 2026, per Panabee's Q3 summary, against $72.6 million on 30 June 2026 in the 10-Q filed 7 August 2026. Net cash at closing sets both the dividend and the exchange ratio.
- The per-share payout is unknown. The 424B3 gives only the aggregate range. The board sets the dividend record date near closing, and Nasdaq sets the ex-dividend date.
- The remaining stake is small and has no operating business. Holders are expected to own about 3.8% fully diluted at an estimated exchange ratio of about 8.6737. The oncology pipeline is discontinued, and the lead asset, SERP-01, is licensed from YolTech Therapeutics, which keeps Greater China rights.
- The vote asks for more than the deal. Holders are asked to approve the share issuance, a reverse stock split between 1-for-10 and 1-for-60, and more authorized shares. A failed vote or a financing shortfall would end the merger case.
- Little price progress since the deal. The shares are 13.1% lower over three months, and the 50-day average of $2.58 sits above the last close.
Price setup
The shares closed at $2.46 on 12 November 2026, below the 50-day average of $2.58 and above the 200-day average of $1.97. The 52-week intraday high is $3.16 (24 August 2026). The 52-week closing low is $1.05 (4 February 2026). The shares closed at $2.83 on 14 August 2026, the reference point for the three-month change.
The special distribution will restate dividend-adjusted price history on the ex-date. The levels in this note use the pre-distribution adjusted series.
Catalysts ahead
- 3 December 2026: Special meeting of Boundless Bio shareholders on the Serapha merger, reverse split and authorized-share increase. Shareholder approval is a closing condition; a failed vote ends the merger case.
- Before closing, date not set: Board declaration of the per-share pre-closing dividend, record date and ex-dividend date. Converts the $44–48 million aggregate estimate into a per-share figure that can be compared with the share price.
- 31 December 2026: End of the guided fourth-quarter 2026 closing window. Completion ends the current instrument and changes the symbol to AATD; a miss or termination breaks the case.
What would change the view
A daily close above $3.00, near the 52-week intraday high of $3.16 set on 24 August 2026, which would show the shares leading the S&P 500 and prove the lag call wrong.
What it trades with
The shares trade on deal terms and cash returned, not on biotech sector moves. The oncology pipeline is discontinued, so clinical readouts from peers do not bear on the stock. Merger-arbitrage and special-situation names with a pending shareholder vote are the closest comparison. The main sensitivities are closing risk and the net-cash estimate.
The evidence, claim by claim (7)
- Boundless Bio set its special meeting for 3 December 2026 at 11:00 a.m. Pacific Time, online, with an 20 October 2026 record date and 23,188,581 shares outstanding on that date. Boundless Bio Form 424B3, SEC EDGAR · as of
- The prospectus describes an aggregate pre-closing special dividend of about $44–48 million, with no per-share amount, and a closing expected in the fourth quarter of 2026. Boundless Bio Form 424B3, SEC EDGAR · as of
- Estimated exchange ratio is about 8.6737; pre-merger holders are expected to own about 3.8% of the combined company fully diluted; Serapha pre-closing financing is about $92 million. Boundless Bio Form 424B3, SEC EDGAR · as of
- Cash, cash equivalents and short-term investments were $62.9 million at 30 September 2026, versus $72.6 million at 30 June 2026. Panabee Q3 2026 earnings summary; Boundless Bio Form 10-Q filed 7 August 2026 · as of
- Kevin Tang, a 10% owner, bought 149,474 shares in the open market at an average $2.34 on 16 October to 20 October 2026, and further shares at $2.40 through 10 November 2026. SEC Form 4 filings · as of
- Kevin Tang sold 18,300 shares in the open market at $2.97 on 26 August 2026. SEC Form 4, filed 28 August 2026 · as of
- Boundless Bio filed its quarterly report (Form 10-Q) with the SEC. SEC EDGAR filing index · as of
Sources
Related · shared themes
GPN
Global Payments
Global Payments trades on a reported $40 billion CD&R and GTCR buyout, and nine brokers raised targets after in-line third-quarter results…
ADT
ADT
ADT Inc. trades as a pending $10.00-per-share cash buyout by Thrive Holdings, so its shares are more likely to lag the S&P 500 than lead…
BMBL
Bumble
Bumble's shares are likely to trail the S&P 500 because they trade as a pending $6.05-per-share cash takeover by Ithaca Holdings, closing…
BRZE
Braze
Salesforce's agreed $47.50-per-share cash takeover of Braze caps the shares just under the offer, so they are more likely to lag the S&P…